Sotorasib (Lumakras) for colorectal cancer – pro
Lumakras is approved for KRAS-mutated lung cancers. There are some studies on teh sue of this drug for colon cacner.
Sotorasib (Soto), a KRASG12C inhibitor, showed modest clinical activity as monotherapy in heavily pretreated patients (pts) with KRAS G12C-mutated colorectal cancer (CRC) in the CodeBreaK 100 phase II study, with a 9.7% objective response rate (ORR). Early data from the CodeBreaK 101 phase Ib dose exploration (n=8) and expansion (n=18) cohorts showed promising antitumor activity for the combination of Soto and panitumumab (Pmab), an EGFR antibody, in chemorefractory KRAS G12C-mutated metastatic CRC (mCRC).
Farikh reported that an objective response to monotherapy was observed in six (9·7%, 95% CI 3·6-19·9) of 62 patients, all with partial response. These results missed the preset expectation.
F. Sloulidis et al, Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med 2021; 384:2371-2381
Y. Kuboki et al, 315O – Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. Annals of Oncology (2022) 33 (suppl_7): S136-S1
Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation
Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207-17. doi:10.1056/NEJMoa1917239